Literature DB >> 33974124

Role of Histone Deacetylases in Monocyte Function in Health and Chronic Inflammatory Diseases.

Rosa María Tordera1, María Cortés-Erice2.   

Abstract

Histone deacetylases (HDACs) are a family of 18 members that participate in the epigenetic regulation of gene expression. In addition to histones, some HDACs also deacetylate transcription factors and specific cytoplasmic proteins.Monocytes, as part of the innate immune system, maintain tissue homeostasis and help fight infections and cancer. In these cells, HDACs are involved in multiple processes including proliferation, migration, differentiation, inflammatory response, infections, and tumorigenesis. Here, a systematic description of the role that most HDACs play in these functions is reviewed. Specifically, some HDACs induce a pro-inflammatory response and play major roles in host defense. Conversely, other HDACs reprogram monocytes and macrophages towards an immunosuppressive phenotype. The right balance between both types helps monocytes to respond correctly to the different physiological/pathological stimuli. However, aberrant expressions or activities of specific HDACs are associated with autoimmune diseases along with other chronic inflammatory diseases, infections, or cancer.This paper critically reviews the interesting and extensive knowledge regarding the role of some HDACs in these pathologies. It also shows that as yet, very little progress has been made toward the goal of finding effective HDAC-targeted therapies. However, given their obvious potential, we conclude that it is worth the effort to develop monocyte-specific drugs that selectively target HDAC subtypes with the aim of finding effective treatments for diseases in which our innate immune system is involved.

Entities:  

Keywords:  Autoimmune diseases; Cancer; Epigenetics; HDACs inhibitors; Immunosuppression; Inflammation; Macrophage reprogramming; Viral infection

Year:  2021        PMID: 33974124     DOI: 10.1007/112_2021_59

Source DB:  PubMed          Journal:  Rev Physiol Biochem Pharmacol        ISSN: 0303-4240            Impact factor:   5.545


  1 in total

1.  Romidepsin (FK228) improves the survival of allogeneic skin grafts through downregulating the production of donor-specific antibody via suppressing the IRE1α-XBP1 pathway.

Authors:  Yuliang Guo; Siyu Song; Xiaoxiao DU; Li Tian; Man Zhang; Hongmin Zhou; Zhonghua Klaus Chen; Sheng Chang
Journal:  J Zhejiang Univ Sci B       Date:  2022-05-15       Impact factor: 5.552

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.